Skip to main content
SpringerLink
Log in

Implantable Contraception

  • Chapter
  • First Online:
The Handbook of Contraception

Part of the book series: Current Clinical Practice ((CCP))

  • 793 Accesses

Abstract

Contraceptive implants are a highly effective form of progestin-only contraception. The implant(s) are placed subdermally, are effective for several years, and their contraceptive effects are rapidly reversible. There are few medical contraindications to contraceptive implants; women with a history of a blood clot, women who are breastfeeding, adolescents, and women with obesity are all candidates to use contraceptive implants. The implant is placed in the upper arm by a clinician who has completed a company-mandated training program. Women may experience menstrual bleeding changes with the implant. These symptoms can be managed medically if a woman finds them bothersome. Clinicians should discuss the contraceptive implant when counseling women about contraceptive options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Meirik O, Fraser IS, d’Arcangues C, WHO Consultation on Implantable Contraceptives for Women. Implantable contraceptives for women. Hum Reprod Update. 2003;9:49–59.

    CAS  PubMed  Google Scholar 

  2. Sivin I, Alvarez F, Mishell DR Jr, et al. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception. 1998;58:275–82.

    CAS  PubMed  Google Scholar 

  3. Kuiper H, Miller S, Martinez E, Loeb L, Darney P. Urban adolescent females’ views on the implant and contraceptive decision-making: a double paradox. Fam Plan Perspect. 1997;29:167–72.

    CAS  Google Scholar 

  4. Steiner MJ, Lopez LM, Grimes DA, et al. Sino-implant (II)--a levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials. Contraception. 2010;81:197–201.

    CAS  PubMed  Google Scholar 

  5. Sivin I, Mishell DR Jr, Diaz S, et al. Prolonged effectiveness of Norplant(R) capsule implants: a 7-year study. Contraception. 2000;61:187–94.

    CAS  PubMed  Google Scholar 

  6. Dunson TR, Amatya RN, Krueger SL. Complications and risk factors associated with the removal of Norplant implants. Obstet Gynecol. 1995;85:543–8.

    CAS  PubMed  Google Scholar 

  7. Meckstroth KR, Darney PD. Implant contraception. Semin Reprod Med. 2001;19:339–54.

    CAS  PubMed  Google Scholar 

  8. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103.

    PubMed  Google Scholar 

  9. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care. 1999;4:67–73.

    CAS  PubMed  Google Scholar 

  10. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965–76.

    CAS  PubMed  Google Scholar 

  11. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. 1998;57:315–24.

    Google Scholar 

  12. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91:1646–53.

    PubMed  Google Scholar 

  13. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.

    CAS  PubMed  Google Scholar 

  14. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception. 2001;64:125–33.

    CAS  PubMed  Google Scholar 

  15. Brito MB, Ferriani RA, Meijers JC, et al. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: a randomized controlled trial. Thromb Res. 2012;130:355–60.

    CAS  PubMed  Google Scholar 

  16. Egberg N, van Beek A, Gunnervik C, et al. Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Contraception. 1998;58:93–8.

    CAS  PubMed  Google Scholar 

  17. Biswas A, Viegas OA, Bennink HJ, Korver T, Ratnam SS. Effect of Implanon use on selected parameters of thyroid and adrenal function. Contraception. 2000;62:247–51.

    CAS  PubMed  Google Scholar 

  18. Biswas A, Viegas OA, Roy AC. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids--a randomized comparative study. Contraception. 2003;68:189–93.

    CAS  PubMed  Google Scholar 

  19. Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception. 2002;65:47–62.

    CAS  PubMed  Google Scholar 

  20. Suherman SK, Affandi B, Korver T. The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception. 1999;60:281–7.

    CAS  PubMed  Google Scholar 

  21. Oderich CL, Wender MC, Lubianca JN, Santos LM, de Mello GC. Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study. Contraception. 2012;85:173–6.

    CAS  PubMed  Google Scholar 

  22. Braga GC, Ferriolli E, Quintana SM, Ferriani RA, Pfrimer K, Vieira CS. Immediate postpartum initiation of etonogestrel-releasing implant: a randomized controlled trial on breastfeeding impact. Contraception. 2015;92:536–42.

    CAS  PubMed  Google Scholar 

  23. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding compared to those of an intrauterine device). Contraception. 2000;62:239–46.

    CAS  PubMed  Google Scholar 

  24. Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sa MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception. 2009;80:519–26.

    CAS  PubMed  Google Scholar 

  25. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol. 2011;117:1114–21.

    PubMed  Google Scholar 

  26. Carmo L, Braga GC, Ferriani RA, Quintana SM, Vieira CS. Timing of etonogestrel-releasing implants and growth of breastfed infants: a randomized controlled trial. Obstet Gynecol. 2017;130:100–7.

    CAS  PubMed  Google Scholar 

  27. Han L, Teal SB, Sheeder J, Tocce K. Preventing repeat pregnancy in adolescents: is immediate postpartum insertion of the contraceptive implant cost effective? Am J Obstet Gynecol. 2014;211:24.e1–7.

    Google Scholar 

  28. Abma JC, Martinez GM. Sexual activity and contraceptive use among teenagers in the United States, 2011–2015. Natl Health Stat Rep. 2017:1–23.

    Google Scholar 

  29. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception. 2011;84:493–8.

    PubMed  PubMed Central  Google Scholar 

  30. Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in postpartum adolescents: bleeding pattern, efficacy and discontinuation rate. Contraception. 2010;82:256–9.

    CAS  PubMed  Google Scholar 

  31. ACOG Committee Opinion No. 735: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2018;131:e130–e9.

    Google Scholar 

  32. Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007–2009. Fertil Steril. 2012;98:893–7.

    PubMed  PubMed Central  Google Scholar 

  33. Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception. 1998;58:283–8.

    CAS  PubMed  Google Scholar 

  34. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998;58:91S–7S.

    CAS  PubMed  Google Scholar 

  35. Makarainen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998;69:714–21.

    CAS  PubMed  Google Scholar 

  36. Brache V, Faundes A, Johansson E, Alvarez F. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants. Contraception. 1985;31:261–73.

    CAS  PubMed  Google Scholar 

  37. Varma R, Mascarenhas L. Endometrial effects of etonogestrel (Implanon) contraceptive implant. Curr Opin Obstet Gynecol. 2001;13:335–41.

    CAS  PubMed  Google Scholar 

  38. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404.

    PubMed  PubMed Central  Google Scholar 

  39. Ali M, Akin A, Bahamondes L, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31:2491–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol. 2017;216:586.e1–6.

    CAS  Google Scholar 

  41. Bouquier J, Fulda V, Bats AS, Lecuru F, Huchon C. A life-threatening ectopic pregnancy with etonogestrel implant. Contraception. 2012;85:215–7.

    PubMed  Google Scholar 

  42. Mornar S, Chan LN, Mistretta S, Neustadt A, Martins S, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol. 2012;207:110.e1–6.

    CAS  Google Scholar 

  43. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120:21–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Levine JP, Sinofsky FE, Christ MF, Implanon US Study Group. Assessment of Implanon insertion and removal. Contraception. 2008;78:409–17.

    PubMed  Google Scholar 

  45. Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception. 2017;95:571–7.

    CAS  PubMed  Google Scholar 

  46. Schindlbeck C, Janni W, Friese K. Failure of Implanon contraception in a patient taking carbamazepin for epilepsia. Arch Gynecol Obstet. 2006;273:255–6.

    PubMed  Google Scholar 

  47. Lange J, Teal S, Tocce K. Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report. J Med Case Rep. 2014;8:43-1947-8-43.

    Google Scholar 

  48. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012;85:425–7.

    CAS  PubMed  Google Scholar 

  49. Neary M, Chappell CA, Scarsi KK, et al. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. J Antimicrob Chemother. 2019;74:3003–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Chappell CA, Lamorde M, Nakalema S, et al. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. AIDS. 2017;31:1965–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Scarsi K, Lamorde M, Darin K, et al. Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc. 2014;17:19484.

    PubMed  PubMed Central  Google Scholar 

  52. Perry SH, Swamy P, Preidis GA, Mwanyumba A, Motsa N, Sarero HN. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS (London, England). 2014;28:791–3.

    Google Scholar 

  53. Todd CS, Deese J, Wang M, et al. Sino-implant (II)(R) continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. Contraception. 2015;91:248–52.

    CAS  PubMed  Google Scholar 

  54. Adams K, Beal MW. Implanon: a review of the literature with recommendations for clinical management. J Midwifery Womens Health. 2009;54:142–9.

    PubMed  Google Scholar 

  55. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception. 2011;83:202–10.

    CAS  PubMed  Google Scholar 

  56. Abdel-Aleem H, d’Arcangues C, Vogelsong KM, Gaffield ML, Gulmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev. 2013;10:CD003449.

    Google Scholar 

  57. Simmons KB, Edelman AB, Fu R, Jensen JT. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial. Contraception. 2017;95:198–204.

    CAS  PubMed  Google Scholar 

  58. Zigler RE, Madden T, Ashby C, Wan L, McNicholas C. Ulipristal acetate for unscheduled bleeding in etonogestrel implant users: a randomized controlled trial. Obstet Gynecol. 2018;132:888–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports. 2016;65:1–66.

    Google Scholar 

  60. Darney PD, Callegari LS, Swift A, Atkinson ES, Robert AM. Condom practices of urban teens using Norplant contraceptive implants, oral contraceptives, and condoms for contraception. Am J Obstet Gynecol. 1999;180:929–37.

    CAS  PubMed  Google Scholar 

  61. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016;30:2665–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Folger SG, Jamieson DJ, Godfrey EM, Zapata LB, Curtis KM. Evidence-based guidance on selected practice recommendations for contraceptive use: identification of research gaps. Contraception. 2013;87:517–23.

    PubMed  Google Scholar 

  63. Mansour D, Mommers E, Teede H, et al. Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. Contraception. 2010;82:243–9.

    PubMed  Google Scholar 

  64. Creinin MD, Kaunitz AM, Darney PD, et al. The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience. Contraception. 2017;95:205–10.

    PubMed  Google Scholar 

  65. Nelson AL. Neutralizing pH of lidocaine reduces pain during Norplant system insertion procedure. Contraception. 1995;51:299–301.

    CAS  PubMed  Google Scholar 

  66. Reed S, Do Minh T, Lange JA, Koro C, Fox M, Heinemann K. Real world data on Nexplanon(R) procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA). Contraception. 2019;100:31–6.

    PubMed  Google Scholar 

  67. Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F, Llabres S, Autret-Leca E, le reseau des centres regionaux de pharmacovigilance. Insertion problems, removal problems, and contraception failures with implanon. Gynecol Obstet Fertil. 2005;33:986–90.

    CAS  PubMed  Google Scholar 

  68. Ismail H, Mansour D, Singh M. Migration of implanon. J Fam Plann Reprod Health Care. 2006;32:157–9.

    PubMed  Google Scholar 

  69. Laumonerie P, Blasco L, Tibbo ME, et al. Peripheral nerve injury associated with a subdermal contraceptive implant: illustrative cases and systematic review of literature. World Neurosurg. 2018;111:317–25.

    PubMed  Google Scholar 

  70. Kang S, Niak A, Gada N, Brinker A, Jones SC. Etonogestrel implant migration to the vasculature, chest wall, and distant body sites: cases from a pharmacovigilance database. Contraception. 2017;96:439–45.

    CAS  PubMed  Google Scholar 

  71. Mommers E, Blum GF, Gent TG, Peters KP, Sordal TS, Marintcheva-Petrova M. Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial. Am J Obstet Gynecol. 2012;207:388.e1–6.

    CAS  Google Scholar 

  72. Singh M, Mansour D, Richardson D. Location and removal of non-palpable Implanon implants with the aid of ultrasound guidance. J Fam Plann Reprod Health Care. 2006;32:153–6.

    PubMed  Google Scholar 

  73. James P, Trenery J. Ultrasound localisation and removal of non-palpable Implanon implants. Aust N Z J Obstet Gynaecol. 2006;46:225–8.

    PubMed  Google Scholar 

  74. Shulman LP, Gabriel H. Management and localization strategies for the nonpalpable Implanon rod. Contraception. 2006;73:325–30.

    PubMed  Google Scholar 

  75. Nouri K, Pinker-Domenig K, Ott J, Fraser I, Egarter C. Removal of non-palpable Implanon(R) with the aid of a hook-wire marker. Contraception. 2013;88:577–80.

    PubMed  Google Scholar 

  76. Chen MJ, Creinin MD. Removal of a nonpalpable etonogestrel implant with preprocedure ultrasonography and modified vasectomy clamp. Obstet Gynecol. 2015;126:935–8.

    PubMed  Google Scholar 

  77. Sivin I, Lahteenmaki P, Ranta S, et al. Levonorgestrel concentrations during use of levonorgestrel ROD (LNG ROD) implants. Contraception. 1997;55:81–5.

    CAS  PubMed  Google Scholar 

  78. Wan LS, Stiber A, Lam LY. The levonorgestrel two-rod implant for long-acting contraception: 10 years of clinical experience. Obstet Gynecol. 2003;102:24–6.

    CAS  PubMed  Google Scholar 

  79. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30:2527–38.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Kansas, Kansas City, KS, USA

    Valerie French

Authors
  1. Valerie French
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valerie French .

Editor information

Editors and Affiliations

  1. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Donna Shoupe

Electronic Supplementary Material

Video 7.1, Part 1

Removal of a deeply inserted etonogestrel implant with a modified vasectomy clamp. After making a skin incision over the implant, the straight hemostat clamp is used to divide the subcutaneous tissue until the level of the implant, as determined by the preprocedure ultrasound study. The modified vasectomy clamp grasps around the implant and brings it to the skin surface. A scalpel is used to clear any overlying fibrotic tissue to free the implant for removal. (Video author: Melissa J. Chen, MD, MPH. Videographer: Courtney Overstreet. Participants: Mitchell D. Creinin, MD, and Melissa J. Chen, MD, MPH. Video courtesy of Melissa J. Chen, MD, MPH. Orginally publication: Chen and Creinin [76]. Used with permission) (PNG 1396 kb)

Video 7.1, Part 2

Scan this image to view Video 7.1 on your smartphone (PNG 50 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

French, V. (2020). Implantable Contraception. In: Shoupe, D. (eds) The Handbook of Contraception. Current Clinical Practice. Humana, Cham. https://doi.org/10.1007/978-3-030-46391-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-46391-5_7

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-46390-8

  • Online ISBN: 978-3-030-46391-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation